These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Acute effects of extracorporeal LDL cholesterol and fibrinogen elimination on blood rheology and microcirculation]. Kleophas W; Leschke M; Tschöpe D; Martin J; Schauseil S; Schottenfeld Y; Strauer BE; Gries FA Dtsch Med Wochenschr; 1990 Jan; 115(1):3-7. PubMed ID: 2295300 [TBL] [Abstract][Full Text] [Related]
26. Extracorporeal LDL elimination with immunabsorption or heparin precipitation: a comparison in 10 patients. Richter WO; Vierneisel K; Schwandt P Beitr Infusionsther; 1988; 23():127-31. PubMed ID: 2484766 [No Abstract] [Full Text] [Related]
27. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy]. Seidel D Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597 [TBL] [Abstract][Full Text] [Related]
28. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Coker M; Ucar SK; Simsek DG; Darcan S; Bak M; Can S Ther Apher Dial; 2009 Apr; 13(2):121-8. PubMed ID: 19379151 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
30. [Heparin-induced extacorporeal low-density lipoprotein-lipoprotein alpha-fibrinogen precipitation in 36 cases]. Mo JK; Li YX; Lei D; Wu DH Di Yi Jun Yi Da Xue Xue Bao; 2002 Mar; 22(3):278-9. PubMed ID: 12390791 [TBL] [Abstract][Full Text] [Related]
31. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]. Thiery J; Seidel D Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888 [TBL] [Abstract][Full Text] [Related]
32. [Myocardial perfusion under H.E.L.P. -apheresis. Objectification by PET]. Mellwig KP; Baller D; Schmidt HK; V Buuren F; Wielepp JP; Burchert W; Horstkotte D Z Kardiol; 2003; 92(Suppl 3):III30-7. PubMed ID: 14663599 [TBL] [Abstract][Full Text] [Related]
33. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Schuff-Werner P; Schütz E; Seyde WC; Eisenhauer T; Janning G; Armstrong VW; Seidel D Eur J Clin Invest; 1989 Feb; 19(1):30-7. PubMed ID: 2499459 [TBL] [Abstract][Full Text] [Related]
34. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
35. Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. Homma K; Homma Y; Yoshida T; Ozawa H; Shiina Y; Wakino S; Hayashi K; Itoh H; Hori S J Clin Lipidol; 2015; 9(2):210-6. PubMed ID: 25911077 [TBL] [Abstract][Full Text] [Related]
37. Apheresis technologies for prevention and regression of atherosclerosis: clinical results. Bambauer R; Schneidewind JM; Latza R ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615 [TBL] [Abstract][Full Text] [Related]
38. [Coronary revascularization with reduction of serum cholesterol level using LDL apheresis in patient with homozygous familial hypercholesterolemia]. Takahashi T; Ihara K; Matsumiya G; Mizutani S; Hasegawa J; Sato S; Nakamura T; Kawamoto T; Nagai Y; Arai T Kokyu To Junkan; 1990 Sep; 38(9):925-30. PubMed ID: 2236967 [TBL] [Abstract][Full Text] [Related]
39. Regression of transplant coronary artery disease during chronic HELP therapy: a case study. Park JW; Vermeltfoort M; Braun P; May E; Merz M Atherosclerosis; 1995 May; 115(1):1-8. PubMed ID: 7669080 [TBL] [Abstract][Full Text] [Related]
40. [H.E.L.P. apheresis and oxidative stress]. Pulawski E; Mellwig KP; Horstkotte D Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]